Stable, protracted glp-1/glucagon receptor co-agonists for medical use
AssigneeNovo Nordisk A/S
InventorsUlrich Sensfuss, Thomas Kruse, Jesper F. Lau
Life of this patent
Estimating the term…
Abstract
The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
Claims26
A glucagon derivative comprising:
- a peptide comprising the amino acid sequence His-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-Tyr-Leu-X15-X16-X17-X18-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-X29-X30;
- a substituent comprising a lipophilic moiety and at least three negatively charged moieties;
- and
- a C-terminal amide;
- wherein,
- X2 represents Aib, Acb or Acpr;
- X3 represents Gln or His;
- X10 represents Leu, Ile or Val;
- X12 represents Lys or Arg;
- X15 represents Asp or Glu;
- X16 represents Ser, Ala, Leu, Thr, Glu, Aib, Ile, Val or Lys;
- X17 represents Arg or Lys;
- X18 represents Arg, Ala or Lys;
- X20 represents Gln, Arg, Glu, Aib or Lys;
- X21 represents Asp, Glu, Ser, or Lys;
- X24 represents Gln, Ala, Arg, Glu, Aib or Lys;
- X27 represents Met, Leu or Val;
- X28 represents Asn, Ser, Thr, Gln, Ala, Gly, Glu or Lys;
- X29 represents Thr, Gly, Ser, Gln, Ala, Glu or Lys;
- and
- X30 represents Lys or is absent;
- wherein Lys is present at one or more positions selected from the group consisting of X12, X16, X17, X18, X20, X21, X24, X28, X29, and X30
- wherein said substituent comprises Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-;
- wherein Z1 is
- n is 6-20, and the symbol * represents the attachment point to the nitrogen of a neighbouring group;
- wherein Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, and Z10 individually are absent or an amino acid selected from the group consisting of Glu, γGlu, Gly, Ser, Ala, Thr, and Ado;
- wherein at least two of residues Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, and Z10 are present;
- wherein Z1-Z2-Z3-Z4-Z3-Z6-Z7-Z8-Z3-Z10 together contains at least three negative charges;
- wherein one of said negatively charged moieties is distal of said lipophilic moiety;
- and
- wherein said substituent is attached to said peptide at the epsilon position of a Lys residue at one amino acid position selected from the group consisting of X16, X17, X18, X20, X21, X24, X28, X29, and X30;
- or a pharmaceutically acceptable salt or prodrug thereof.
A glucagon peptide consisting of (i) a C-terminal amide and (ii) the amino acid sequence of SEQ ID NO:
- 1 modified by a set of modifications selected from the group consisting of:
- a) [Aib2,Leu10,Lys16,Arg20,Leu27,Ser28];
- b) [Aib2,Leu10,Arg20,Lys21,Leu27,Ser28];
- c) [Aib2,Leu10,Arg20,Lys24,Leu27,Ser28];
- d) [Aib2,Leu10,Arg20,Leu27,Lys28];
- e) [Aib2,Leu10,Arg20,Leu27,Ser28,Lys29];
- f) [Aib2,Leu10,Arg20,Leu27,Ser28];
- g) [Aib2,Leu10,Lys16,Lys17,Glu21,Leu27];
- h) [Aib2,Leu10,Lys17,Ala18,Glu21,Leu27,Lys29];
- i) [Aib2,Leu10,Ala18,Arg20,Glu21,Leu27,Lys29];
- j) [Aib2,Leu10,Lys16,Arg20,Glu21,Leu27];
- k) [Aib2,Leu10,Thr16,Lys20,Leu27,Ser28,Lys29];
- l) [Aib2,Leu10,Arg20,Glu21,Leu27,Lys29];
- m) Aib2,Leu10,Glu16,Lys20,Leu27,Ser28,Lys29];
- n) [Aib2,Leu10,Lys16,Glu20,Leu27,Ser28,Lys29];
- o) [Aib2,Leu10,Thr16,Arg24,Leu27,Ser28,Lys29];
- p) [Acb2,Leu10,Glu15,Glu16,Arg20,Leu27,Lys28];
- q) [Aib2,Leu10,Lys16,Lys17,Ala18,Arg20,Glu21,Ala24,Leu27];
- r) [Aib2,Leu10,Lys16,Ala18,Arg20,Glu21,Ala24,Leu27];
- s) [Aib2,Leu10,Lys16,Arg20,Glu21,Ala24,Leu27];
- t) [Aib2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- u) [Aib2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys29];
- v) [Aib2,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys28];
- w) [Aib2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- x) [Aib2,Leu10,Glu15,Lys17,Ala18,Arg20,Glu21,Leu27,Lys28];
- y) [Aib2,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys28];
- z) [Aib2,Leu10,Leu16,Lys17,Arg20,Glu21,Leu27,Lys28];
- aa) [Aib2,His3,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys2 8];
- bb) [Aib2,Leu10,Lys16,Glu21,Val27,Lys28,Gly29];
- cc) [Aib2,Leu10,Lys16,Glu21,Leu27];
- dd) [Aib2,His3,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- ee) [Aib2,His3,Leu10,Glu15,Arg20,Glu21,Ala24,Leu27,Lys2 8];
- ff) [Aib2,His3,Leu10,Glu15,Lys16,Arg20,Glu21,Ala24,Leu27,Ser28];
- gg) [Aib2,His3,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- hh) [Aib2,His3,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys2 8];
- ii) [Acb2,His3,Leu10,Glu15,Leu27,Lys28];
- jj) [Acb2,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys28]
- kk) [Aib2,His3,Leu10,Glu15,Arg20,Leu27,Lys28];
- ll) [Aib2,Leu10,Leu16,Arg20,Glu21,Leu27,Lys29];
- mm) [Aib2,Leu10,Ala16,Arg20,Glu21,Leu27,Lys29];
- nn) [Aib2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys29];
- oo) [Aib2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- pp) [Aib2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- qq) [Aib2,Leu10,Ala16,Arg20,Glu21,Leu27,Lys28];
- rr) [Acb2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- ss) [Acb2,Leu10,Leu16,Arg20,Leu27,Lys28];
- tt) [Acb2,Leu10,Arg12,Leu16,Arg20,Leu27,Lys28];
- uu) [Acb2,Leu10,Leu16,Lys17,Arg20,Glu21,Leu27,Lys28];
- vv) [Acb2,Leu10,Leu16,Lys17,Arg20,Glu21,Leu27,Lys28];
- ww) [Acb2,Leu10,Leu16,Arg20,Glu21,Leu27,Lys28];
- xx) [Acpr2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- yy) [Aib2,Leu10,Aib16,Arg20,Glu21,Leu27,Lys28];
- zz) [Aib2,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys28];
- aaa) [Aib2,Leu10,Leu16,Leu27,Lys28];
- bbb) [Aib2,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys28];
- ccc) [Aib2,Leu10,Leu16,Arg20,Leu27,Lys28];
- ddd) [Aib2,Leu10,Arg20,Glu21,Leu27,Lys28];
- eee) [Aib2,Leu10,Glu15,Arg20,Leu27,Lys28];
- fff) [Aib2,Leu10,Ala16,Arg20,Leu27,Lys28];
- ggg) [Acb2.Leu10.Arg12.Glu15.Arg20,Glu21,Leu27,Lys28];
- hhh) [Aib2.Leu10.Glu15,Arg20,Glu21,Leu27,Lys28];
- iii) [Acb2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- jjj) [Aib2,Leu10,Arg12,Ala16,Arg20,Leu27,Lys28];
- kkk) [Acb2,Leu10,Glu15,Leu27,Lys28];
- lll) [Aib2,Leu10,Arg12,Ala16,Leu27,Lys28];
- mmm) [Aib2,Leu10,Ala16,Arg20,Leu27,Lys29];
- nnn) [Aib2,Leu10,Ala16,Arg20,Leu27,Ser28,Lys29];
- ooo) [Aib2,Leu10,Glu15,Arg20,Glu21,Leu27,Lys28];
- ppp) [Aib2,Leu10,Arg12,Glu15,Arg20,Glu21,Leu27,Lys28];
- qqq) [Acb2,Leu10,Glu15,Lys17,Arg20,Glu21,Leu27,Lys28];
- rrr) [Aib2,Leu10,Glu15,Lys17,Arg20,Ser21,Leu27,Lys28];
- sss) [Aib2,Val10,Ala16,Leu27,Lys28];
- ttt) [Aib2,Val10,Leu16,Leu27,Lys28];
- uuu) [Aib2,Val10,Arg12,Ala16,Leu27,Lys28];
- vvv) [Aib2,Val10,Arg12,Leu16,Leu27,Lys28];
- or a pharmaceutically acceptable salt, amide, or ester thereof.
A pharmaceutical composition comprising (i) a glucagon derivative and (ii) a GLP-1 compound or an insulin compound;
- wherein the glucagon derivative comprises a peptide comprising the amino acid sequence His-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-Tyr-Leu-X15-X16-X17-X18-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-X20-X30;
- a substituent comprising a lipophilic moiety and at least three negatively charged moieties;
- and a C-terminal amide;
- wherein,
- X2 represents Aib, Acb or Acpr;
- X3 represents Gln or His;
- X10 represents Leu, Ile or Val;
- X12 represents Lys or Arg;
- X15 represents Asp or Glu;
- X16 represents Ser, Ala, Leu, Thr, Glu, Aib, Ile, Val or Lys;
- X17 represents Arg or Lys;
- X18 represents Arg, Ala or Lys;
- X20 represents Gln, Arg, Glu, Aib or Lys;
- X21 represents Asp, Glu, Ser, or Lys;
- X24 represents Gln, Ala, Arg, Glu, Aib or Lys;
- X27 represents Met, Leu or Val;
- X28 represents Asn, Ser, Thr, Gln, Ala, Gly, Glu or Lys;
- X29 represents Thr, Gly, Ser, Gln, Ala, Glu or Lys;
- and
- X30 represents Lys or is absent;
- wherein Lys is present at one or more positions selected from the group consisting of X12, X16, X17, X18, X20, X21, X24, X28, X29, and X30;
- wherein said substituent comprises Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-;
- wherein Z1 is
- n is 6-20, and the symbol * represents the attachment point to the nitrogen of a neighbouring group;
- wherein Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, and Z10 individually are absent or an amino acid selected from the group consisting of Glu, γGlu, Gly, Ser, Ala, Thr, and Ado;
- wherein at least two of residues Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, and Z10 are present;
- wherein Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10 together contains at least three negative charges;
- wherein one of said negatively charged moieties is distal of said lipophilic moiety;
- and
- wherein said substituent is attached to said peptide at the epsilon position of a Lys residue at one amino acid position selected from the group consisting of X16, X17, X18, X20, X21, X24, X28, X29, and X30;
- or a pharmaceutically acceptable salt or prodrug thereof.
A method of treating a disease or condition by administering to a patient in need thereof a glucagon derivative, or a pharmaceutically acceptable salt or prodrug thereof, comprising:
- a peptide comprising the amino acid sequence His-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-Tyr-Leu-X15-X16-X17-X18-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-X29-X30;
- a substituent comprising a lipophilic moiety and at least three negatively charged moieties;
- and a C-terminal amide;
- wherein,
- X2 represents Aib, Acb or Acpr;
- X3 represents Gln or His;
- X10 represents Leu, Ile or Val;
- X12 represents Lys or Arg;
- X15 represents Asp or Glu;
- X16 represents Ser, Ala, Leu, Thr, Glu, Aib, Ile, Val or Lys;
- X17 represents Arg or Lys;
- X18 represents Arg, Ala or Lys;
- X20 represents Gln, Arg, Glu, Aib or Lys;
- X21 represents Asp, Glu, Ser, or Lys;
- X24 represents Gln, Ala, Arg, Glu, Aib or Lys;
- X27 represents Met, Leu or Val;
- X28 represents Asn, Ser, Thr, Gln, Ala, Gly, Glu or Lys;
- X29 represents Thr, Gly, Ser, Gln, Ala, Glu or Lys;
- and
- X30 represents Lys or is absent;
- wherein Lys is present at one or more positions selected from the group consisting of X12, X16, X17, X18, X20, X21, X24, X28, X29, and X30;
- wherein said substituent comprises Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-;
- wherein Z1 is
- n is 6-20, and the symbol * represents the attachment point to the nitrogen of a neighbouring group;
- wherein Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, and Z10 individually are absent or an amino acid selected from the group consisting of Glu, γGlu, Gly, Ser, Ala, Thr, and Ado;
- wherein at least two of residues Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9, and Z10 are present;
- wherein Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10 together contains at least three negative charges;
- wherein one of said negatively charged moieties is distal of said lipophilic moiety;
- and
- wherein said substituent is attached to said peptide at the epsilon position of a Lys residue at one amino acid position selected from the group consisting of X16, X17, X18, X20, X21, X24, X28, X29, and X30;
- wherein the disease or condition is selected from the group consisting of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, and overweight.
The method according to claim 21, wherein the substituent is selected from the group consisting of:
- wherein * indicates the point of attachment to said peptide at the nitrogen atom of the epsilon position of a Lys residue.
Dependencies are inferred from the claim text.